Innovent Biologics and Eli Lilly and Company have entered a strategic collaboration agreement to accelerate the global development of new medicines in the fields of oncology and immunology.
Bristol Myers Squibb (BMS) has entered an agreement with Microsoft to advance AI-driven early lung cancer detection.
Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T cell (Treg) therapy to treat myelofibrosis, a rare blood cancer.
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneously (SC) administered therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Takeda and Innovent have closed their global partnership for next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, following the fulfilment of all closing conditions.
Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a $3.05bn cash deal.
Myrio Therapeutics has announced a collaborative partnership with NYU Langone Health and the University of Pennsylvania Perelman School of Medicine to expedite next-generation T cell immunotherapeutics development for solid tumours.
Citius Oncology has entered into an agreement with McKesson for the distribution of Lymphir (denileukin diftitox-cxdl).
Avenzo Therapeutics, a clinical-stage biotechnology company, has closed a $60m series B financing round to advance the development of its oncology drug candidates.
BeOne Medicines has received the European Commission (EC) approval for Brukinsa’s (zanubrutinib) new film-coated tablet formulation for all approved indications.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.